Dermatology

An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.

An expert in dermatology highlights emerging biologic therapy for the management of HS.

Renata Block, MMS, PA-C, comments on the use of biologic agents as part of immunomodulatory therapy for HS treatment.

In this interview with Dr. Baldwin, she spoke on her team’s recent research and its application to rosacea and other dermatologic conditions.

The long-awaited approval for VP-102 makes this treatment the first available therapy for the pox virus-borne skin disease.

An expert in dermatology reviews the current standard of care for treating patients with mild-to-moderate HS and discusses unmet needs in the clinical management of the condition.

Renata Block, MMS, PA-C, provides insight on the prevalence, symptoms, and predisposing factors that contribute to hidradenitis suppurativa (HS).

This new data could be valuable for follow-up appointments with patients who have cutaneous squamous cell carcinoma and for skin cancer services.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

In his interview, Dr. Amin discusses his views on the FDA’s recent approval of ritlecitinib for the treatment of adolescent patients with alopecia areata.

For this segment of her interview, Dr. Mellerio further discussed the contents of her talk on new treatment options for epidermolysis bullosa, highlighting DEB and EB simplex.

In this interview segment, Dr. Mellerio spoke about the contents of her presentation titled ‘New Treatment Approaches for Epidermolysis Bullosa.’

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.

This new research highlighted the value of engaging Mohs surgery patients in shared decision-making to find the best pain control plan for their needs.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

Both biologic-naïve and biologic-experience patients saw benefits in the BRIGHT study examining therapeutic response to brodalumab over the course of 1 year.

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

New research on patients with pemphigus highlighted the heavy mental burden on those with these conditions and the importance of screening for anxiety, depression, and quality of life.

New data drawn from the EUSTAR database made clear several key insights into this subset of systemic sclerosis patients, with survival and skin manifestations being highlighted.